ModerateFixed-dose combination: aminopenicillin plus beta-lactamase inhibitor×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative
Updated · Methodology
Mechanism
The documents describe no pharmacokinetic interaction. Amoxicillin is eliminated mainly by the kidneys, and clavulanic acid by both renal and non-renal routes (Augmentine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Tranylcypromine is metabolised in the liver, and its metabolites are excreted in the urine and bile. Among cytochrome P450 enzymes, it strongly inhibits only CYP2A6, which plays little role in the metabolism of most drugs (tranylcypromine SmPC, AEMPS). The shared point is the liver. Severe and, in extremely rare cases, fatal liver injury with amoxicillin and clavulanic acid has almost always occurred in people with serious underlying disease or in those taking other medicines with known potential hepatic effects (Augmentine SmPC, AEMPS). Tranylcypromine is one of them: hepatitis and raised aminotransferases have been reported with it (Parnate label, US Food and Drug Administration, FDA).
Symptoms
The documents describe no symptoms specific to this combination. Liver injury with amoxicillin and clavulanic acid shows as raised liver enzymes, hepatitis or cholestatic jaundice and can appear during treatment or several weeks after it ends (Augmentine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Tranylcypromine rarely causes hepatic failure and raised liver enzymes (tranylcypromine SmPC, AEMPS). Seizures are possible with both: amoxicillin and clavulanic acid can cause them in renal impairment or at high doses, and tranylcypromine can lower the seizure threshold (SmPCs of both drugs, AEMPS).
Management
No document names the pair, and no dose change is required, but the combination is used with liver monitoring. Severe liver injury with amoxicillin and clavulanic acid has almost always occurred in people taking medicines with potential hepatic effects (Augmentine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). During tranylcypromine treatment, liver function is monitored, and tranylcypromine is stopped if signs of liver injury appear (Parnate label, US Food and Drug Administration, FDA). Tranylcypromine is contraindicated in liver disease (tranylcypromine SmPC, AEMPS). Amoxicillin and clavulanic acid is used with caution in hepatic impairment, and liver function is checked regularly. During prolonged treatment, renal, hepatic and haematopoietic function is assessed periodically (Augmentine SmPC, AEMPS). The amoxicillin and clavulanic acid dose is adjusted to renal function, because seizures can occur in renal impairment and at high doses (Augmentine SmPC, AEMPS). Tranylcypromine is used with caution in epilepsy, and people at risk of seizures are monitored (tranylcypromine SmPC, AEMPS; Parnate label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.3 (2026)– AEMPS, CIMA, nº registro 88524, revisión 08/2026, sección 4.3
- FDA: Parnate (tranylcypromine) prescribing information (2025)– FDA, DailyMed, Advanz Pharma, setid b72d8187-dfcc-4ea0-b5e9-c0be95b69a27, revised 07/2025, sections 4.1, 5.3, 5.9 and 7.1
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.5 (2026)– AEMPS, CIMA, nº registro 88524 (Tranilcipromina Aristo 20 mg comprimidos recubiertos con película; autorizado, no comercializado), revisión 08/2026 (texto revisado 04/2026), secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.1
- AEMPS: Ficha técnica: Amoxicilina/ácido clavulánico, Augmentine 500 mg/125 mg (nº registro 81482), secciones 4.4 y 4.5 (2024)– AEMPS, CIMA, nº registro 81482 (Augmentine 500 mg/125 mg comprimidos recubiertos con película, GlaxoSmithKline; mismo texto sobre anticoagulantes orales en 4.5 de Augmentine suspensión, nº 59051, y sobres, nº 56683), revisión 07/2024, secciones 4.4, 4.5 y 4.8
- FDA: Augmentin ES-600 (amoxicillin and clavulanate potassium) prescribing information (2026)– FDA, DailyMed setid 59979859-8c9b-4173-a5e3-2e6312fd9d79 (USAntibiotics), versión 6, 07/2026, secciones 4 y 7.2